An analysis of 16 studies showed that CAR T-cell therapy is safe and effective for relapsed/refractory mantle cell lymphoma.

Testing for ESR1 mutations is essential after ER-positive HER2-negative breast cancer progressed.

The DetermalO identified patients with early-stage triple-negative breast cancer who would benefit from presurgical atezolizumab plus carboplatin and nab-paclitaxel.

The FDA granted namodenoson an orphan drug designation for patients who have pancreatic cancer.

Weekly MR-Linac adaptive radiotherapy limited exposure to normal brain tissue in patients with high-grade glioma.

Adding talazoparib to enzalutamide improved survival in patients with metastatic castration-resistant prostate cancer.

NT-17, a long-acting IL-7 agent, enhances CAR T-cell factors associated with efficacy in patients with relapsed/refractory DLBCL when administered 21 days post-CAR T infusion.

Inavolisib plus palbociclib and fulvestrant was approved for the treatment of PIK3CA-mutant, HR-positive, HER2-negative locally advanced or metastatic breast cancer.

The staging of small cell lung cancer significantly impacts treatment plans and potential side effects.

A supplemental biologics license application was submitted for telisotuzumab vedotin for the treatment of metastatic EGFR wild-type nonsquamous non–small cell lung cancer.

Patients with breast cancer who are of childbearing age may face issues that are accentuated by their age, an expert explained.

Pelvic transposition may improve quality of life and preserve fertility in patients with gynecologic cancer undergoing pelvic radiation.

A nurse practitioner discussed considerations for managing aromatase inhibitor-related joint pain in patients with breast cancer.

The World Health Organization updated their guidelines to include CINtec PLUS Cytology for gynecologic cancer prevention.

As biomarkers continue to be explored in resectable melanoma, oncology nurses will play a crucial role in the clinical trial process.

An expert explained the role oncology nurses and advanced practice providers play in caring for patients with sarcoma during treatment.

Panelists conclude by discussing the future of graft-versus-host disease management, expressing their hopes for the current treatment landscape and potential advancements that could further improve patient outcomes and quality of life.

Panelists discuss how axatilimab, a novel therapy for chronic graft-versus-host disease (cGVHD), functions through a unique mechanism of action compared to other treatments, highlighting its potential role in cGVHD management and presenting key findings from the AGAVE-201 trial that demonstrate its efficacy and safety profile.

The addition of nivolumab to radiotherapy significantly improved freedom from biochemical recurrence in patients with high-grade prostate cancer.

P-BCMA-ALLO1 elicited high response rates and a manageable safety profile in heavily pretreated, relapsed/refractory multiple myeloma.

Oral drugs in the HR-positive, HER2-negative metastatic breast cancer space put a focus on clear patient-provider communication about adherence and adverse events.

The FDA granted a priority review to acalabrutinib for the treatment of previously untreated adults with mantle cell lymphoma.

The FDA approved neoadjuvant nivolumab plus chemo, followed by adjuvant nivolumab for non-small cell lung cancer without EGFR mutations or ALK rearrangements.

Follow-up from the CARTITUDE-4 trial showed that cilta-cel improved survival over standard of care in pretreated myeloma.

Cilta-cel led to high response rates and a promising safety profile in a real-world population of patients with relapsed/refractory myeloma.